A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis

Table 1

Clinical characteristics of 139 patients with sHLH.

Characteristics	Median	Quartile
WBC (×10^9/L)	2.22	1.2–4.59
HGB (g/L)	89	78–109
PLT (×10^9/L)	54	27–114
CRP (mg/L)	22	5–78.05
ALT (U/L)	94	42–198.25
AST (U/L)	90.9	40.8–220.8
LDH (U/L)	529.5	314.85–1069.5
γ-GT (U/L)	116	50–270
ALP (U/L)	156	93–337
TBil (umol/L)	22.1	15.12–54
Alb (g/L)	30	24.1–34
Glb (g/L)	25.9	20.8–30.7
Scr (umol/L)	60.3	50.9–76.3
BUN (mmol/L)	5.23	4.03–7.29
TG (mmol/L)	2.48	1.77–3.55
K (mmol/L)	3.91	3.67–4.25
Ca (mmol/L)	2.04	1.91–2.15
Na (mmol/L)	135.9	132.1–138.8
CO2CP	24.4	22.7–26.7
Fg (g/L)	1.675	1.1475–3.28
SF (ng/ml)	2385	1286.75–11409.95
sCD25 (pg/ml)	26271	15957.65–40939.75
NK cell activity (%)	14.675	12.97–16.29
CD107a (%)	13.15	8.47–20.31
EBV-DNA (copy/ml)	9.9 E + 002	0–4.7475 E + 004
D-dimer (mg/L)	2.6	1.1–8.2

WBC, white blood cell; HBG, hemoglobin; PLT, platelet; CRP, C-reactive protein; ALT, alanine transferase; AST, aspartate aminotransferase; LDH, lactic dehydrogenase;,γ-GT: γ-glutamyl transpeptidase; ALP, alkaline phosphatase; Fg, fibrinogen; CO2CP, carbon dioxide combining power; NK cell activity, natural killer cell activity; EBV, Epstein-Barr virus.